41-50 of 77 results
Looks can be deceiving: deceptive similarity, substantial identity and trade mark infringement
This Insights examines the interpretative requirements for determining a trade mark infringement ...
Allens lends a hand to Global Health
Allens has advised the Global Health Investment Fund ( GHIF ), a private investment fund whose mission is to finance late-stage drugs, vaccines and diagnostics for diseases that disproportionately ...
Allens advises Archer Capital on sale of Healthe Care
Allens has advised Archer Capital on its proposed divestment of private hospital business Healthe Care to China's Luye Medical Group. Healthe Care is Australia's third largest private hospital ...
Unexpected risks of the IoT revolution: Cyber security in medical devices
In late August 2017 the US Food and Drug Administration recalled 465000 Abbott Laboratories pacemakers due to cyber security vulnerabilities Although this was the first time that the FDA had recalled a medical device because of cyber concerns they have been alive to the significant risk that a cyber ...
Competition news
In Touch looks at what's been happening in Competition this month and what it means for your business ...
Allens helps deliver a healthy hospital outcome
Allens has advised the Plenary Health consortium on the expansion of the existing Casey Hospital through a series of transactions that closed late last week. The expansion will significantly increa ...
Allens advises financiers on Icon Group acquisition
Allens has advised Credit Suisse AG and Goldman Sachs Australia as financiers of the acquisition of the Icon Group, Australia's largest private cancer and oncology services group. The acquisition, ...
Protecting investment in biologic medicines - biological medicines, biosimilars and the challenges they pose
This series of articles is directed towards the part of biotech that is pharmaceutical rather than diagnostic or bioengineering technologies and in particular towards biologic medicines ...
What's in a (biosimilar) name?
Because biosimilars and their reference biologic medicine are not identical whether compared to each other or even between biosimilars it is important to know which product has been used ...
Costs before Caution - Australia's unique approach to the interchangeability of biosimilars
Recent developments in Australia suggest that there has been a deliberate prioritisation of the cost benefits of facilitating biosimilar interchangeability over the safety and efficacy risks that can arise when biosimilars are used interchangeably ...